Año: 2012
Journal Impact Factor (JIF): 3.0730
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| PHARMACOLOGY & PHARMACY | SCIE | 72/261 | Q2 | T1 | D3 |
| INFECTIOUS DISEASES | SCIE | 22/70 | Q2 | T1 | D4 |
| VIROLOGY | SCIE | 13/34 | Q2 | T2 | D4 |
Año: 2017
Journal Citation Indicator (JCI): 0,690
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| INFECTIOUS DISEASES | 56/111 | Q3 | T2 | D6 | 50,00 |
| PHARMACOLOGY & PHARMACY | 171/336 | Q3 | T2 | D6 | 49,26 |
| VIROLOGY | 22/39 | Q3 | T2 | D6 | 44,87 |
Año:
2012
CiteScore:
5,000
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Infectious Diseases | 48/230 | Q1 | T1 | D3 |
| Pharmacology (medical) | 50/218 | Q1 | T1 | D3 |
| Pharmacology | 83/305 | Q2 | T1 | D3 |
SJR año:
2012
Factor de Impacto:
1,303
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Infectious Diseases | 56/288 | Q1 | T1 | D2 |
| Pharmacology | 63/357 | Q1 | T1 | D2 |
| Pharmacology (medical) | 37/274 | Q1 | T1 | D2 |
| Agencia | Código de Proyecto |
|---|---|
| Abbott | - |
| BMS | - |
| Boehringer | - |
| Bristol-Myers Squibb | - |
| Gilead | - |
| Gilead Sciences | - |
| Instituto de Salud Carlos III through Red Tematica de Investigacion Cooperativa en Sida (ISCIII-RETIC) | RD06/006 |
| Jansen-Cilag | - |
| Janssen | - |
| Merck Sharp Dohme | - |
| MSD | - |
| Roche | - |
| ViiV | - |
| ViiV Healthcare | - |
| # | Autor |
|---|---|
| 1 | Sobrino-Vegas, P |
| 2 | Rodriguez-Urrego, J |
| 3 | Berenguer, J |
| 4 | Caro-Murillo, AM |
| 5 | Blanco, JR |
| 6 | Viciana, P |
| 7 | Moreno, S |
| 8 | Bernardino, I |
| 9 | |
| # | Autoría grupal |
| 1 | López Cortés, Luis Fernando, (CoRIS) |